Envíos recientes

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Wiendl, Heinz; Derfuss, Tobias; Chan, Andrew; Barkhof, Frederik; Achiron, Anat; Montalban, Xavier (Frontiers Media, 2025-02-03)

Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction

Arranz Horno, Paula; Fonseca, Elianet; Medina Martínez, Inmaculada; Ariño, Helena; Malagelada, Carolina; Vilaseca Jolonch, Andreu; Llaurado, Arnau; Zabalza, Ana; Alcalá-González, Luis Gerardo; BORRUEL, NATALIA; Montalban, Xavier (Wolters Kluwer Health, 2025-03)

A data-driven model of disability progression in progressive multiple sclerosis

garbarino, sara; Lorenzi, Marco; Pardini, Matteo; PIANA, MICHELE; UCCELLI, Antonio; TUR, CARMEN (Oxford University Press, 2025)

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

Corominas Garcia, Júlia; Garriga, Carme; Prenafeta, Antoni; Moros, Alexandra; Cañete, Manuel; Barreiro, Antonio; Camacho-Arteaga, Lina ; Otero-Romero, Susana; Martínez-Gómez, Xavier (Elsevier, 2025-02-15)

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Lunemann, Jan; Valls Carbó, Adrián; Fernández, Victoria; Bollo, Luca; Villacieros-Álvarez, Javier; Sepulveda, Maria; Dinoto, Alessandro; Vilaseca Jolonch, Andreu; Castillo Juárez, Mireia; Espejo, Carmen; Cobo-Calvo, Alvaro; Tintore, Mar; Comabella Lopez, Manuel; Arrambide, Georgina; Montalban, Xavier (Wolters Kluwer Health, 2025-01)

Scientia. Depósito de Información Digital del Departamento de Salud

CEMCAT - Articles científics: Envíos recientes

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction

A data-driven model of disability progression in progressive multiple sclerosis

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Scientia. Depósito de Información Digital del Departamento de Salud

CEMCAT - Articles científics: Envíos recientes

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study ﻿

Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction ﻿

A data-driven model of disability progression in progressive multiple sclerosis ﻿

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial ﻿

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease ﻿

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction

A data-driven model of disability progression in progressive multiple sclerosis

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease